Trial Profile
Randomized Clinical Trial for the Prevention of Cognitive Impairment in Atrial Fibrillation Patients Treated With Dabigatran or Warfarin
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Jan 2022
Price :
$35
*
At a glance
- Drugs Dabigatran etexilate (Primary) ; Warfarin
- Indications Embolism and thrombosis; Stroke
- Focus Pharmacodynamics
- Acronyms GIRAF
- 15 Nov 2021 Primary endpoint has been met. (Cognitive function), as per Results presented at the American Heart Association Scientific Sessions 2021
- 15 Nov 2021 Results presented at the American Heart Association Scientific Sessions 2021
- 28 Sep 2021 Status changed from active, no longer recruiting to completed.